Holen Sie sich die Stockscreener-App
1.08
6.90%
-0.08
Handel nachbörslich:
1.06
-0.02
-1.85%
Schlusskurs vom Vortag:
$1.16
Offen:
$1.18
24-Stunden-Volumen:
1.19M
Relative Volume:
1.09
Marktkapitalisierung:
$108.39M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.31M
KGV:
-4.0832
EPS:
-0.2645
Netto-Cashflow:
$-21.07M
1W Leistung:
+0.93%
1M Leistung:
+22.30%
6M Leistung:
+66.15%
1J Leistung:
+6.93%
1-Tages-Spanne:
$1.06
$1.19
1-Wochen-Bereich:
$1.01
$1.245
52-Wochen-Spanne:
$0.3258
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ONCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.08 | 116.43M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Technical signs of recovery in Oncolytics Biotech Inc.July 2025 PostEarnings & Real-Time Volume Analysis - Newser
Is Oncolytics Biotech Inc. likely to announce a buyback2025 Price Action Summary & Daily Stock Trend Watchlist - khodrobank.com
Is Oncolytics Biotech Inc. still worth holding after the dip2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
What is Oncolytics Biotech Inc.’s TAM (Total Addressable Market)July 2025 Opening Moves & AI Forecast for Swing Trade Picks - khodrobank.com
Applying big data sentiment scoring on Oncolytics Biotech Inc.Market Sentiment Summary & High Conviction Buy Zone Picks - Newser
Can Oncolytics Biotech Inc. reach all time highs this yearEarnings Summary Report & Verified Stock Trade Ideas - khodrobank.com
Quantitative breakdown of Oncolytics Biotech Inc. recent moveWeekly Profit Report & Fast Gaining Stock Reports - Newser
Can momentum traders help lift Oncolytics Biotech Inc.July 2025 Outlook & Fast Entry High Yield Tips - Newser
Can Oncolytics Biotech Inc. stock outperform in a bear marketPortfolio Growth Summary & High Win Rate Trade Tips - khodrobank.com
How to use a screener to detect Oncolytics Biotech Inc. breakoutsMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Cellectar Biosciences shares fall 1.24% premarket as Oncolytics Biotech Inc. gains FDA approval for breakthrough therapies. - AInvest
How hedge fund analytics apply to Oncolytics Biotech Inc. stock2025 Valuation Update & Advanced Technical Analysis Signals - Newser
What’s the recovery path for long term holders of Oncolytics Biotech Inc.Earnings Performance Report & Stepwise Entry and Exit Trade Signals - Newser
Multi asset correlation models including Oncolytics Biotech Inc.2025 Historical Comparison & Free Growth Oriented Trading Recommendations - Newser
Oncolytics Biotech shares rise 8.70% premarket after providing updated clinical safety data for pelareorep. - AInvest
What technical models suggest about Oncolytics Biotech Inc.’s comebackWeekly Stock Report & Safe Capital Growth Trade Ideas - Newser
What moving averages say about Oncolytics Biotech Inc.Inflation Watch & Target Return Focused Picks - Newser
Using data filters to optimize entry into Oncolytics Biotech Inc.July 2025 Short Interest & Verified High Yield Trade Plans - Newser
Tools to assess Oncolytics Biotech Inc.’s risk profileGap Down & Fast Entry and Exit Trade Plans - Newser
Does Oncolytics Biotech Inc. qualify in momentum factor screening2025 Market Sentiment & Safe Entry Trade Reports - Newser
Leading vs lagging indicators on Oncolytics Biotech Inc. performanceQuarterly Profit Review & Target Return Focused Stock Picks - Newser
Using portfolio simulators with Oncolytics Biotech Inc. included2025 Top Decliners & Long-Term Safe Investment Plans - Newser
FDA Fast-Track Cancer Treatments Drive Market Surge as Innovations Accelerate - Baystreet.ca
How to forecast Oncolytics Biotech Inc. trends using time series - Newser
Oncolytics Biotech Inc. recovery potential after sell off2025 Top Decliners & Fast Gain Swing Trade Alerts - Newser
Trend analysis for Oncolytics Biotech Inc. this weekJuly 2025 Institutional & Technical Buy Zone Confirmation - Newser
Cellectar Biosciences shares fall 1.45% after-hours as Oncolytics Biotech Inc. gains regulatory momentum. - AInvest
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands - The Ritz Herald
Oncolytics Biotech Updates Pelareorep Safety Data for Gastrointestinal Tumors - TipRanks
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors - Barchart.com
Published on: 2025-09-02 05:28:33 - Newser
Aug Setups: Will Oncolytics Biotech Inc. benefit from geopolitical trendsJuly 2025 Short Interest & Risk Managed Investment Signals - khodrobank.com
Pattern recognition hints at Oncolytics Biotech Inc. upsideMarket Volume Report & Expert Curated Trade Setups - Newser
Will Oncolytics Biotech Inc. stock recover after recent drop2025 Analyst Calls & Weekly High Return Forecasts - Newser
What’s the RSI of Oncolytics Biotech Inc. stockJuly 2025 Final Week & Daily Stock Trend Watchlist - khodrobank.com
Market reaction to Oncolytics Biotech Inc.’s recent newsJuly 2025 Momentum & Consistent Profit Alerts - Newser
What moving averages say about Oncolytics Biotech IncJuly 2025 Reactions & Free Safe Capital Growth Stock Tips - Newser
Developing predictive dashboards with Oncolytics Biotech Inc. data2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):